Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults

The treatment of inflammatory arthritis has been revolutionised by the introduction biologic treatments. Many agents are currently licensed for use in both paediatric and adult patients with contribute to improved disease outcomes compared pre-biologic era. However, immunogenicity agents, characterised an immune reaction leading production anti-drug antibodies (ADAs), can negatively impact therapeutic efficacy drugs induce side effects treatment. This review explores first time against all treatments used across age, will examine any significant differences between ADA prevalence, titres timing development, as well on drug levels, clinical patients. In addition, we investigate factors associated arthritis, their potential implications.